DrugPatentWatch Database Preview
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
« Back to Dashboard
Gossypol is an investigational drug.
There have been 10 clinical trials for Gossypol. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2013.
The most common disease conditions in clinical trials are Lung Neoplasms, Small Cell Lung Carcinoma, and Leukemia, Lymphocytic, Chronic, B-Cell. The leading clinical trial sponsors are National Cancer Institute (NCI), Mayo Clinic, and Third Military Medical University.
There are seven hundred and eighty-three US patents protecting this investigational drug and four international patents.
Recent Clinical Trials for Gossypol
|R-(-)-Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma||National Cancer Institute (NCI)||Phase 1/Phase 2|
|R-(-)-Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple Myeloma||Mayo Clinic||Phase 1/Phase 2|
|Lenalidomide and AT-101 in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia||National Cancer Institute (NCI)||Phase 1/Phase 2|
Top disease conditions for Gossypol
Top clinical trial sponsors for Gossypol
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Gossypol||Start Trial||Heterocyclic compounds useful in the treatment of disease||Epigen Biosciences, Inc. (San Diego, CA)||Start Trial|
|Gossypol||Start Trial||Pyrazol-3-ones that activate pro-apoptotic BAX||Dana-Farber Cancer Institute, Inc. (Boston, MA)||Start Trial|
|Gossypol||Start Trial||Small molecules for the modulation of MCL-1 and methods of modulating cell death, cell division, cell differentiation and methods of treating disorders||Dana-Farber Cancer Institute, Inc. (Boston, MA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|